Quinazoline derivatives

本申请涉及式(I)的喹唑啉衍生物及其盐[其中：Y#+[1]表示-O-、-S-、-CH#-[2]-、-SO-、-SO#-[2]-、-NR#+[5]CO-、-CONR#+[6]-、-SO#-[2]NR#+[7]-、-NR#+[8]SO#-[2]-或-NR#+[9]-(其中R#+[5]、R#+[6]、R#+[7]、R#+[8]和R#+[9]各自独立地表示氢原子、烷基或烷氧基烷基)；R#+[1]表示氢原子、羟基、卤原子、硝基、三氟甲基、氰基、烷基、烷氧基、烷硫基、氨基或烷基氨基；R#+[2]表示氢原子、羟基、卤原子、烷基、烷氧基、三氟甲基、氰基、氨基或硝基；m是1至5的整数；R#+[3]表示羟基、卤原子、烷基、烷氧基、烷酰氧基、三氟甲基、氰基、氨基或硝基；R#+[4]表示是或含有任选取代的吡啶酮基、苯基或芳杂环基]；其制备方法及含有式(I)化合物或其可药用盐作为活性成分的药物组合物。式(I)化合物及其可药用盐抑制VEGF的作用，该性质使其在治疗包括癌症及类风湿性关节炎等若干疾病中具有一定价值。∴ The invention relates to quinazoline derivatives of the formula: [wherein: Y1 represents -O-, -S-, -CH2-, -SO-, -SO2-, -NR5CO-, -CONR6-, -SO2NR7-, -NR8SO2- or -NR9- (wherein R5, R6, R7, R8 and R9 each independently represents hydrogen, alkyl or alkoxyalkyl); R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino. R2 represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro; m is an integer from 1 to 5; R3 represents hydroxy, halogeno, alky, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R4 represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.